The University of Houston has teamed up with Chevron for a new fellowship program, which just announced its first class. Photo courtesy of UH.edu

The University of Houston has named eight graduate students to its first-ever cohort of UH-Chevron Energy Graduate Fellows.

The PhD and doctoral students will each receive a one-year $12,000 fellowship, along with mentoring from experts at UH and Chevron.

“The UH-Chevron Energy Fellowship program is an exciting opportunity for our graduate students to research the many critical areas that impact the energy industry, our communities and our global competitiveness,” Ramanan Krishnamoorti UH's Vice President for Energy and Innovation says in a statement.

“Today’s students not only recognize the importance of energy, but they are actively driving the push for affordable, reliable, sustainable and secure energy and making choices that clearly indicate that they are meaningfully contributing to the change,” he continues.

Their work focuses on energy-related research in fields ranging from public policy to geophysics and math. The fellowship is funded by Chevron.

“We love that Chevron is sponsoring this group of fellows because it’s a fantastic way for us to get involved with the students who are working on some of the biggest problems we’ll face in society,” Chevron Technology Ventures President Jim Gable adds.

The 2023 UH-Chevron Energy Graduate Fellows are:

The PhD and doctoral students will each receive a one-year $12,000 fellowship, along with mentoring from experts at UH and Chevron. Photo via UH.edu

Kripa Adhikari, a Ph.D. student in the Department of Civil and Environmental Engineering in the Cullen College of Engineering. Her work focuses on thermal regulation in enhanced geothermal systems. She currently works under the mentorship of Professor Kalyana Babu Nakshatrala and previously worked as a civil engineer with the Nepal Reconstruction Authority.

Aparajita Datta, a researcher at UH Energy and a Ph.D. candidate in the Department of Political Science. Her work focuses on the federal Low-Income Home Energy Assistance Program (LIHEAP), a redistributive welfare policy designed to help households pay their energy bills. She holds a bachelor’s degree in computer science and engineering from the University of Petroleum and Energy Studies in India, and master’s degrees in energy management and public policy from UH. She also recently worked on a paper for UH about transportation emissions.

Chirag Goel, a Ph.D. student in materials science and engineering at UH. His work focuses on using High Temperature Superconductors (HTS) to optimize manufacturing processes, which he says can help achieve carbon-free economies by 2050. The work has uses in renewable energy generation, electric power transmission and advanced scientific applications.

Meghana Idamakanti, a third-year Ph.D. student in the William A. Brookshire Department of Chemical and Biomolecular Engineering. Her work focuses on using electrically heated steam methane for cleaner hydrogen production. She received her bachelor’s degree in chemical engineering from Jawaharlal Nehru Technological University in India in 2020 and previously worked as a process engineering intern at Glochem Industries in India.

Erin Picton, an environmental engineering Ph.D. student in the Shaffer Lab at UH. Her work focuses on ways to increase the sustainability of lithium processing and reducing wasted water and energy. “I love the idea of taking waste and turning it into value,” she said in a statement. She has previously worked in collaboration with MIT and Greentown Labs, as chief sustainability officer of a Houston-based desalination startup; and as a visiting graduate researcher at Argonne National Lab and at INSA in Lyon, France.

Mohamad Sarhan, a Ph.D. student and a teaching assistant in the Department of Petroleum Engineering. His work focuses on seasonal hydrogen storage and the stability of storage candidates during hydrogen cycling. He holds a bachelor’s degree and a master’s degree in petroleum engineering from Cairo University

Swapnil Sharma, a Ph.D. student in the William A. Brookshire Department of Chemical and Biomolecular Engineering. His work has been funded by the Department of Energy and focuses on thermal modeling of large-scale liquid hydrogen storage tanks. He works with Professor Vemuri Balakotaiah. He holds bachelor's and master’s degrees in chemical engineering from the Indian Institute of Technology (IIT). He also developed one of the world’s highest fiber-count optical fiber cables while working in India and founded CovRelief, which helped millions of Indians find resources about hospital beds, oxygen suppliers and more during the pandemic.

Larkin Spires, who's working on her doctoral research in the Department of Earth and Atmospheric Sciences in the College of Natural Sciences and Mathematics. Her work focuses on a semi-empirical Brown and Korringa model for fluid substitution and the ties between geophysics and mathematics. She works under Professor John Castagna and holds a bachelor’s degree in math from Louisiana State University and a master’s degree in geophysics from UH.

Earlier this month Evolve Houston also announced its first-ever cohort of 13 microgrant recipients, whose work aims to make EVs and charging infrastructure more accessible in some of the city's more underserved neighborhoods.

------

This article originally ran on EnergyCapital.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston digital health platform Koda lands strategic investment

money moves

Houston-based advance care planning platform Koda Health has added another investor to the lineup.

The company secured a strategic investment for an undisclosed amount from UPMC Enterprises, the commercialization arm of the University of Pittsburgh Medical Center. The funding is part of Koda's oversubscribed series A funding round that closed in October, according to a release.

"UPMC Enterprises’ investment is a meaningful signal, not just to Koda, but to the broader market," Dr. Desh Mohan, chief medical officer and co-founder of Koda Health, said in the news release. "It validates that health systems are ready to invest in infrastructure that makes advance care planning work the way it should: proactively, at scale, and with the human support that these conversations require. Having UPMC Enterprises as a strategic investor puts us in a unique position to prove what's possible."

Koda has raised $14 million to date, according to a representative from the company. Its series A round was led by Evidenced, with participation from Mudita Venture Partners, Techstars and the Texas Medical Center last year. At the time, the company said the funding would allow it to scale operations and expand engineering, clinical strategy and customer success. The company described the round as a "pivotal moment," as it had secured investments from influential leaders in the healthcare and venture capital space.

Koda Health, which was born out of the TMC's Biodesign Fellowship in 2020, saw major growth last year, as well, and now supports more than 1 million patients nationwide through partnerships with Cigna Healthcare, Privia Health, Guidehealth, Sentara, UPMC and Memorial Hermann Health System.

The company integrated its end-of-life care planning platform with Dallas-based Guidehealth in April 2025 and with Epic Systems in July 2025. It also won the 2025 Houston Innovation Award in the Health Tech Business category. Read more here.

New 'living pharmacy' biotech company launches out of Rice venture studio

fighting cancer

Rice University’s biotech venture studio RBL LLC has launched a new “living pharmacy” company, Duracyte, designed to make cancer treatment easier on patients.

Backed by an up to $45 million Advanced Research Projects Agency for Health (ARPA-H) award, Duracyte aims to commercialize implantable biohybrid pharmacy devices that are designed to produce therapeutic proteins inside the human body around the clock, replacing the need for regular injections and infusions for some cancer patients.

The company’s main platform is its Hybrid Advanced Molecular Manufacturing Regulator (HAMMR), a rechargeable, implantable device that can sense biological signals, monitor tumor environments and adjust therapeutic output in real time. HAMMR has wireless communication capabilities, which allow patients and clinicians to remotely monitor results through an app every five minutes and make changes to treatment plans without a hosptial visit. Additionally, the device can generate its own oxygen supply, which is key for the therapeutic cells’ survival.

“Biologic medicines such as monoclonal antibodies, cytokines and metabolic regulators already account for a significant share of modern therapeutics, but the way we deliver them today often requires frequent injections or infusions that can be demanding for patients and lead to inconsistent drug levels,” Daniel Anderson, MIT professor and co-founder of Duracyte, said in a news release. “Our vision is to enable a continuous, stable therapy by producing these medicines directly inside the body, which could improve treatment consistency, reduce side effects and ultimately transform how biologic therapies are delivered across many diseases.”

Duracyte’s first clinical trial is slated to begin by the end of 2026 and will focus on recurrent ovarian cancer. The Phase I study will build upon existing work on encapsulated cytokine pharmacy technology, and the company hopes that within a few years this treatment can reach clinical application.

The development of Duracyte is supported by ARPA-H's Targeted Hybrid Oncotherapeutic Regulation (THOR) project, which supports a multidisciplinary research consortium co-led by Omid Veiseh, a professor of bioengineering at Rice. The consortium also includes others at Rice, The University of Texas MD Anderson Cancer Center, Stanford University, Carnegie Mellon University, Northwestern University and the University of Houston, plus industry collaborators like Chicago-based CellTrans.

“What we are building is the culmination of years of progress in cell engineering, biomaterials and implantable device technology,” Veiseh added in the release. “By combining these advances with real-time sensing and adaptive drug delivery, we are working with the support of RBL to create a true ‘living pharmacy’ that can deliver continuous, precisely controlled biologic therapies and fundamentally change how these treatments reach patients.”

RBL launched in 2024 and is based out of Houston’s Texas Medical Center Helix Park. Duracyte is the third company launched by RBL, including Sentinel BioTherapeutics, a clinical-stage immunotherapy company developing localized cytokine therapies for solid tumors, and SteerBio, a regenerative medicine company targeting lymphedema.

“Duracyte exemplifies the kind of breakthrough that Houston’s ecosystem is built to produce,” Paul Wotton, managing partner of RBL LLC and co-founder of Duracyte, added in the release. “With world-class clinical infrastructure, exceptional engineering talent and initiatives like the Texas Biotech Task Force driving alignment across industry, investment and talent, this region is uniquely positioned to move the most ambitious ideas in medicine from concept to patient, faster than anywhere else.”